BGP advises Memo Therapeutics regarding its CHF 14 Mio. Series B financing round

11. November 2020

Bader Gnehm & Partner advised Memo Therapeutics Ltd in a CHF 14 million Series B financing round, involving the investors Swisscanto Invest, BERNINA BioInvest, Redalpine, Jaquet Partners and Schroder Adveq.

Memo Therapeutics Ltd, an innovator in the field of antibody discovery and immune repertoire analysis, intends to use the proceeds to further develop its lead antibody candidate "MTX-COVAB" for the treatment of COVID-19.


Memo Therapeutics Ltd was advised in all legal matters with regard to the Series B financing round by Bader Gnehm & Partner. The team consisted of Oliver Gnehm (Partner), Denis A. Parvex (Associate) and Thomas Gysin (Associate).

Bader Gnehm & Partner has been repeatedly awarded as top law firm in the area of "Private Equity and Venture Capital".

The press release of Memo Therapeutics Ltd can be found here.